Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 35

1.

Selective DNA-PKcs inhibition extends the therapeutic index of localized radiotherapy and chemotherapy.

Willoughby CE, Jiang Y, Thomas HD, Willmore E, Kyle S, Wittner A, Phillips N, Zhao Y, Tudhope SJ, Prendergast L, Junge G, Lourenco LM, Finlay MRV, Turner P, Munck JM, Griffin RJ, Rennison T, Pickles J, Cano C, Newell DR, Reeves HL, Ryan AJ, Wedge SR.

J Clin Invest. 2019 Nov 25. pii: 127483. doi: 10.1172/JCI127483. [Epub ahead of print]

2.

Non-genotoxic MDM2 inhibition selectively induces a pro-apoptotic p53 gene signature in chronic lymphocytic leukemia cells.

Ciardullo C, Aptullahoglu E, Woodhouse L, Lin WY, Wallis JP, Marr H, Marshall S, Bown N, Willmore E, Lunec J.

Haematologica. 2019 Dec;104(12):2429-2442. doi: 10.3324/haematol.2018.206631. Epub 2019 Apr 19.

3.

Scapular dyskinesia: evolution towards a systems-based approach.

Willmore EG, Smith MJ.

Shoulder Elbow. 2016 Jan;8(1):61-70. doi: 10.1177/1758573215618857. Epub 2015 Dec 17.

4.

PARP1 expression, activity and ex vivo sensitivity to the PARP inhibitor, talazoparib (BMN 673), in chronic lymphocytic leukaemia.

Herriott A, Tudhope SJ, Junge G, Rodrigues N, Patterson MJ, Woodhouse L, Lunec J, Hunter JE, Mulligan EA, Cole M, Allinson LM, Wallis JP, Marshall S, Wang E, Curtin NJ, Willmore E.

Oncotarget. 2015 Dec 22;6(41):43978-91. doi: 10.18632/oncotarget.6287.

5.

SKP2 is a direct transcriptional target of MYCN and a potential therapeutic target in neuroblastoma.

Evans L, Chen L, Milazzo G, Gherardi S, Perini G, Willmore E, Newell DR, Tweddle DA.

Cancer Lett. 2015 Jul 10;363(1):37-45. doi: 10.1016/j.canlet.2015.03.044. Epub 2015 Apr 2.

PMID:
25843293
6.

Regulation of p53 and Rb links the alternative NF-κB pathway to EZH2 expression and cell senescence.

Iannetti A, Ledoux AC, Tudhope SJ, Sellier H, Zhao B, Mowla S, Moore A, Hummerich H, Gewurz BE, Cockell SJ, Jat PS, Willmore E, Perkins ND.

PLoS Genet. 2014 Sep 25;10(9):e1004642. doi: 10.1371/journal.pgen.1004642. eCollection 2014 Sep.

7.

Preferential potentiation of topoisomerase I poison cytotoxicity by PARP inhibition in S phase.

Znojek P, Willmore E, Curtin NJ.

Br J Cancer. 2014 Sep 23;111(7):1319-26. doi: 10.1038/bjc.2014.378. Epub 2014 Jul 8.

8.

Identification of dual DNA-PK MDR1 inhibitors for the potentiation of cytotoxic drug activity.

Mould E, Berry P, Jamieson D, Hill C, Cano C, Tan N, Elliott S, Durkacz B, Newell D, Willmore E.

Biochem Pharmacol. 2014 Mar 1;88(1):58-65. doi: 10.1016/j.bcp.2014.01.001. Epub 2014 Jan 10.

PMID:
24418411
9.

Cross-talk between DNA methylation and active histone modifications regulates aberrant expression of ZAP70 in CLL.

Amin S, Walsh M, Wilson C, Parker AE, Oscier D, Willmore E, Mann D, Mann J.

J Cell Mol Med. 2012 Sep;16(9):2074-84. doi: 10.1111/j.1582-4934.2011.01503.x.

10.

NF-κB mediates radio-sensitization by the PARP-1 inhibitor, AG-014699.

Hunter JE, Willmore E, Irving JA, Hostomsky Z, Veuger SJ, Durkacz BW.

Oncogene. 2012 Jan 12;31(2):251-64. doi: 10.1038/onc.2011.229. Epub 2011 Jun 27.

11.

Mitoxantrone in combination with an inhibitor of DNA-dependent protein kinase: a potential therapy for high risk B-cell chronic lymphocytic leukaemia.

Elliott SL, Crawford C, Mulligan E, Summerfield G, Newton P, Wallis J, Mainou-Fowler T, Evans P, Bedwell C, Durkacz BW, Willmore E.

Br J Haematol. 2011 Jan;152(1):61-71. doi: 10.1111/j.1365-2141.2010.08425.x. Epub 2010 Nov 18.

PMID:
21083655
12.

Role of Topoisomerase IIβ in DNA Damage Response following IR and Etoposide.

Sunter NJ, Cowell IG, Willmore E, Watters GP, Austin CA.

J Nucleic Acids. 2010 Aug 19;2010. pii: 710589. doi: 10.4061/2010/710589.

13.

The dietary flavonoids myricetin and fisetin act as dual inhibitors of DNA topoisomerases I and II in cells.

López-Lázaro M, Willmore E, Austin CA.

Mutat Res. 2010 Feb;696(1):41-7. doi: 10.1016/j.mrgentox.2009.12.010. Epub 2009 Dec 16.

PMID:
20025993
14.

Selenite induces topoisomerase I and II-DNA complexes in K562 leukemia cells.

López-Lázaro M, Willmore E, Elliott SL, Austin CA.

Int J Cancer. 2008 Nov 1;123(9):2217-21. doi: 10.1002/ijc.23783.

15.

Effect of phenazine compounds XR11576 and XR5944 on DNA topoisomerases.

Jobson AG, Willmore E, Tilby MJ, Mistry P, Charlton P, Austin CA.

Cancer Chemother Pharmacol. 2009 Apr;63(5):889-901. doi: 10.1007/s00280-008-0812-9. Epub 2008 Aug 5.

PMID:
18679685
16.

DNA-dependent protein kinase is a therapeutic target and an indicator of poor prognosis in B-cell chronic lymphocytic leukemia.

Willmore E, Elliott SL, Mainou-Fowler T, Summerfield GP, Jackson GH, O'Neill F, Lowe C, Carter A, Harris R, Pettitt AR, Cano-Soumillac C, Griffin RJ, Cowell IG, Austin CA, Durkacz BW.

Clin Cancer Res. 2008 Jun 15;14(12):3984-92. doi: 10.1158/1078-0432.CCR-07-5158.

17.

Curcumin induces high levels of topoisomerase I- and II-DNA complexes in K562 leukemia cells.

López-Lázaro M, Willmore E, Jobson A, Gilroy KL, Curtis H, Padget K, Austin CA.

J Nat Prod. 2007 Dec;70(12):1884-8. Epub 2007 Dec 13.

PMID:
18076140
18.

Cells lacking DNA topoisomerase II beta are resistant to genistein.

López-Lazaro M, Willmore E, Austin CA.

J Nat Prod. 2007 May;70(5):763-7. Epub 2007 Apr 6.

PMID:
17411092
19.

Electrolytic lesions of the nucleus accumbens enhance locomotor sensitization to nicotine in rats.

Kelsey JE, Willmore EJ.

Behav Neurosci. 2006 Jun;120(3):600-11.

PMID:
16768612
20.
21.

A novel DNA-dependent protein kinase inhibitor, NU7026, potentiates the cytotoxicity of topoisomerase II poisons used in the treatment of leukemia.

Willmore E, de Caux S, Sunter NJ, Tilby MJ, Jackson GH, Austin CA, Durkacz BW.

Blood. 2004 Jun 15;103(12):4659-65. Epub 2004 Mar 9.

PMID:
15010369
22.

Differences in the longevity of topo IIalpha and topo IIbeta drug-stabilized cleavable complexes and the relationship to drug sensitivity.

Errington F, Willmore E, Leontiou C, Tilby MJ, Austin CA.

Cancer Chemother Pharmacol. 2004 Feb;53(2):155-62. Epub 2003 Sep 23.

PMID:
14504921
23.

Alchemix: a novel alkylating anthraquinone with potent activity against anthracycline- and cisplatin-resistant ovarian cancer.

Pors K, Paniwnyk Z, Teesdale-Spittle P, Plumb JA, Willmore E, Austin CA, Patterson LH.

Mol Cancer Ther. 2003 Jul;2(7):607-10.

25.

Formation and longevity of idarubicin-induced DNA topoisomerase II cleavable complexes in K562 human leukaemia cells.

Willmore E, Errington F, Tilby MJ, Austin CA.

Biochem Pharmacol. 2002 May 15;63(10):1807-15.

PMID:
12034365
26.

Murine transgenic cells lacking DNA topoisomerase IIbeta are resistant to acridines and mitoxantrone: analysis of cytotoxicity and cleavable complex formation.

Errington F, Willmore E, Tilby MJ, Li L, Li G, Li W, Baguley BC, Austin CA.

Mol Pharmacol. 1999 Dec;56(6):1309-16.

PMID:
10570059
27.

Nuclear distribution of human DNA topoisomerase IIbeta: a nuclear targeting signal resides in the 116-residue C-terminal tail.

Cowell IG, Willmore E, Chalton D, Marsh KL, Jazrawi E, Fisher LM, Austin CA.

Exp Cell Res. 1998 Sep 15;243(2):232-40.

PMID:
9743583
29.

Amsacrine-promoted DNA cleavage site determinants for the two human DNA topoisomerase II isoforms alpha and beta.

Marsh KL, Willmore E, Tinelli S, Cornarotti M, Meczes EL, Capranico G, Fisher LM, Austin CA.

Biochem Pharmacol. 1996 Dec 13;52(11):1675-85.

PMID:
8986129
30.

Drug sensitivity and sequence specificity of human recombinant DNA topoisomerases IIalpha (p170) and IIbeta (p180).

Cornarotti M, Tinelli S, Willmore E, Zunino F, Fisher LM, Austin CA, Capranico G.

Mol Pharmacol. 1996 Dec;50(6):1463-71.

PMID:
8967966
31.

Position-specific effects of base mismatch on mammalian topoisomerase II DNA cleaving activity.

Bigioni M, Zunino F, Tinelli S, Austin CA, Willmore E, Capranico G.

Biochemistry. 1996 Jan 9;35(1):153-9.

PMID:
8555169
32.

Expression, domain structure, and enzymatic properties of an active recombinant human DNA topoisomerase II beta.

Austin CA, Marsh KL, Wasserman RA, Willmore E, Sayer PJ, Wang JC, Fisher LM.

J Biol Chem. 1995 Jun 30;270(26):15739-46.

33.

Supplemental Content

Loading ...
Support Center